Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Workers - Hazard via inhalation route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
0.73 mg/m³
Most sensitive endpoint:
repeated dose toxicity
Route of original study:
Oral
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
20
Dose descriptor starting point:
NOAEL
Value:
50 mg/kg bw/day
Modified dose descriptor starting point:
NOAEC
Value:
14.67 mg/m³
Explanation for the modification of the dose descriptor starting point:

Body weight 70 kg

Table R.8 -2: worker 8h exercise : 10 m3/person

Table R.8-5 : subacute to chronic: AF=6

/4 (allometric) * 70kg / 10 m3/ person

AF for interspecies differences (allometric scaling):
4
Justification:
Table R.8-2: rat to human
AF for other interspecies differences:
1
Justification:
no metabolization expected
AF for intraspecies differences:
5
Justification:
Table R8-6 workers
AF for the quality of the whole database:
1
Justification:
GLP or NDA, validated by US-FDA data
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information
Dose descriptor starting point:
NOAEC
Justification:
Conservative choice: systemic exposure expected to be negligible due to rapid eliminination in exhaled air.
AF for the quality of the whole database:
1
Justification:
NDA data audited and validated by US-FDA
AF for remaining uncertainties:
1
Justification:
systemic exposure expected to be negligible.

Local effects

Long term exposure
Hazard assessment conclusion:
no hazard identified
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information

Workers - Hazard via dermal route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
50 mg/kg bw/day
Most sensitive endpoint:
repeated dose toxicity
Route of original study:
Oral
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
10
Dose descriptor starting point:
NOAEL
Value:
50 mg/kg bw/day
AF for differences in duration of exposure:
2
Justification:
NOAEL obtained in a 28 d study.
AF for interspecies differences (allometric scaling):
5
Acute/short term exposure
Hazard assessment conclusion:
low hazard (no threshold derived)
DNEL related information

Local effects

Long term exposure
Hazard assessment conclusion:
no hazard identified
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified

Workers - Hazard for the eyes

Local effects

Hazard assessment conclusion:
no hazard identified

Additional information - workers

General Population - Hazard via inhalation route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
0.73 mg/m³
Most sensitive endpoint:
repeated dose toxicity
Route of original study:
Oral
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
240
Dose descriptor starting point:
NOAEL
Value:
50 mg/kg bw/day
Modified dose descriptor starting point:
NOAEC
Explanation for the modification of the dose descriptor starting point:

inhalation rate, light exercise (RIVM ConsExpo Web, version 1.0.6, 13-02-2019) = 1.25 m3/h

Working day = 1h chosen as worst case: no exposure foreseen for general population

Total volume inhaled = 1.25 m3

Body weight = 70 kg

50 mg/kg/d corresponds to 3500 mg, to be inhaled through 20 m3

General population chronic inhalation NAEC = 175 mg/m3

AF for differences in duration of exposure:
6
Justification:
R8-6 subacute to chronic
AF for interspecies differences (allometric scaling):
4
Justification:
R.8-2 rat to human
AF for intraspecies differences:
10
Justification:
Table R.8-19
AF for the quality of the whole database:
1
Justification:
GLP and FDA validated data
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information
Explanation for the modification of the dose descriptor starting point:

No toxicity was observed in acute toxicity studies.

Local effects

Long term exposure
Hazard assessment conclusion:
no hazard identified
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information

General Population - Hazard via dermal route

Systemic effects

Long term exposure
Hazard assessment conclusion:
hazard unknown but no further hazard information necessary as no exposure expected
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information
Explanation for the modification of the dose descriptor starting point:

No adverse effect observed in acute toxicity studies.

Local effects

Long term exposure
Hazard assessment conclusion:
no hazard identified
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified

General Population - Hazard via oral route

Systemic effects

Long term exposure
Hazard assessment conclusion:
DNEL (Derived No Effect Level)
Value:
250 mg/kg bw/day
Most sensitive endpoint:
repeated dose toxicity
DNEL related information
DNEL derivation method:
ECHA REACH Guidance
Overall assessment factor (AF):
5
Dose descriptor starting point:
NOAEL
Value:
250 mg/kg bw/day
AF for differences in duration of exposure:
1
Justification:
General population is not expected to be exposed to tetradecafluorohexane.
AF for interspecies differences (allometric scaling):
5
Justification:
As tetradecafluorohexane is eliminated rapidly due to high volatility, no significant systemic exposure is expected.
an AF 5 is set as a very conservative value
AF for intraspecies differences:
1
Justification:
As tetradecafluorohexane is eliminated rapidly due to high volatility, no significant systemic exposure is expected without influence of the differences of metabolism.
AF for the quality of the whole database:
1
Justification:
Data from NDA dossier audited and validated by US-FDA.
AF for remaining uncertainties:
1
Justification:
As the adverse effects were observed after administration of tetradecafluorohexane by IV route, associated with a galenic designed to dramatically enhance systemic exposure, their relevance for oral exposure is expected to be a very conservative hypothesis. therfore, remaining uncertainties are considered already taken into account.
Acute/short term exposure
Hazard assessment conclusion:
no hazard identified
DNEL related information

General Population - Hazard for the eyes

Local effects

Hazard assessment conclusion:
no hazard identified

Additional information - General Population

No exposure expected for the general population.